Virtual Library
Start Your Search
H.S. Moon
Author of
-
+
P1.03 - Chemotherapy/Targeted Therapy (ID 689)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 2
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.03-025 - Combination Therapy with Carboplatin and Hyperoxia Synergistically Enhances Suppression of Benzo[a]Pyrene Induced Lung Cancer (ID 8432)
09:30 - 09:30 | Author(s): H.S. Moon
- Abstract
Background:
We explored the effects of intermittent normobaric hyperoxia alone or combined with chemotherapy on the growth, general morphology, oxidative stress, and apoptosis of benzo[a]pyrene (B[a]P)-induced lung tumors in mice.
Method:
Female A/J mice were given a single dose of B[a]P and randomized into four groups: (1) control, (2) carboplatin (50 mg/kg intraperitoneally), (3) hyperoxia (95% fraction of inspired oxygen), and (4) carboplatin and hyperoxia. Normobaric hyperoxia (95%) was applied for 3 h each day from weeks 21 to 28. Tumor load was determined as the average total tumor numbers and volumes. Several markers of oxidative stress and apoptosis were evaluated.
Result:
Intermittent normobaric hyperoxia combined with chemotherapy reduced the tumor number by 59% and the load by 72% compared with the control B[a]P group. Intermittent normobaric hyperoxia, either alone or combined with chemotherapy, decreased the levels of superoxide dismutase (SOD) and glutathione (GSH) and increased the levels of catalase and 8-hydroxydeoxyguanosine (8-OHdG). The Bax/Bcl-2 mRNA ratio, caspase-3 level, and number of transferase-mediated dUTP nick end-labeling (TUNEL)-positive cells increased following treatment with hyperoxia with or without chemotherapy.
Conclusion:
Intermittent normobaric hyperoxia was found to be tumoricidal and thus may serve as an adjuvant therapy for lung cancer. Oxidative stress and its effects on DNA are increased following exposure to hyperoxia and even more with chemotherapy, and this may lead to apoptosis of lung tumors.
-
+
P1.03-030 - Prognostic Impact of the Presence of COPD in Patients with NSCLC under Conventional Systemic Chemotherapy (ID 8793)
09:30 - 09:30 | Author(s): H.S. Moon
- Abstract
Background:
Effects of the presence of COPD on clinical outcomes in patient with advanced stage NSCLC cancer were inconclusive. Aim of our study is to evaluate the effects of COPD on overall survival of NSCLC patients who undergo conventional chemotherapy as 1st line treatment.
Method:
Advanced NSCLC (stage IIIB and IV) received first-line chemotherapy from January of 2008 to December 2015 were enrolled from 6 university hospitals. Patients who underwent pretreatment pulmonary function test were selected in the analyses, and COPD was defined according to GOLD guideline: FEV1/ FVC < 0.7. Primary endpoint was the overall survival according to the patients’ clinicopathological characteristics.
Result:
A total of 197 patients comprised of 92 patients (46.7%) in the COPD group and 105 (53.3%) in the non-COPD group were enrolled in the analysis. The median duration of follow-up for survived patients was 23.9 months. The presence of COPD was a significant risk factor for mortality in the univariate analysis (HR, 1.402; p = 0.037), however not in the multivariate analysis (HR, 1.275; p = 0.144). The patients with COPD have poor clinical outcomes in subgroups of smokers and stage IV cancer, significantly.
Conclusion:
: COPD does not have clinical impact of overall survival of advanced NSCLC patients who undergo conventional chemotherapy. However COPD was a poor prognostic factor in terms of overall survival of in smokes and stage IV NSCLC patients. Further studies which evaluate clinical effects of airflow obstruction management on lung cancer patients can elucidate the clinical impact of COPD.
